Grassley probes insurer over ‘penalties’ charged for brand-name drugs

first_imgPharmalot Grassley probes insurer over ‘penalties’ charged for brand-name drugs By Ed Silverman April 18, 2017 Reprints Pharmalot Columnist, Senior Writer Ed covers the pharmaceutical industry. Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. After months of targeting drug makers over their pricing, Senator Chuck Grassley is now probing one of the biggest insurers in the mid-Atlantic region, opening what may become another front in the battle over the cost of prescription medicines.The lawmaker has asked CareFirst BlueCross BlueShield to explain a complicated policy that he suspects may force patients to overpay for brand-name medications that doctors have specified must be dispensed. Grassley is also concerned that some people may instead feel they have no choice but to opt for lower-cost generic drugs that, in such situations, may not be as effective. Senator Chuck Grassley Drew Angerer/Getty Images What’s included? Log In | Learn More Unlock this article by subscribing to STAT+ and enjoy your first 30 days free! GET STARTEDcenter_img STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. GET STARTED About the Author Reprints Tags drug pricingpharmaceuticalsSTAT+ What is it? @Pharmalot Ed Silverman [email protected] last_img read more